Advertisement

State of the Art and Future Prospects of the Treatment of Acute Myeloid Leukemia

  • T. Büchner
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 34)

Abstract

Major clinical trials published during the 1980s failed to demonstrate a substantial therapeutic progress in chemotherapy for patients with AML. In particular, it remained unanswered whether more chemotherapy — in terms of its intensity as well as duration — produces more cures. Bone marrow transplantation has not been adequately compared to chemotherapy on the basis of comparable groups. Chemotherapy may be modulated by hemopoietic growth factors in both its myelotoxicity and its antileukemic activity as from first clinical results. We discuss here major results from the above therapeutic approaches and their role in AML management.

Keywords

Cytosine Arabinoside Remission Duration Bone Marrow Blast Relapse Free Survival Acute Nonlymphocytic Leukemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Büchner T, Urbanitz D, Hiddemann Wet al (1985) Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative group. J Clin Oncol 3: 1583–1589PubMedGoogle Scholar
  2. 2.
    Bücher T, Hiddemann W, Koenigsmann Met al (1991) Recominant human granulocyte-macrophage colony-stimulating factor following chemotherapy in patients with acute mayloid leukemia at higher age or after relapse. Blood 78: 1190–1197Google Scholar
  3. 3.
    Büchner T, Hiddemann W, Löffler H et al (1991) Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute mayloid leukemia (AML): data from AMLCG. Semin Hematol 28, Suppl 4: 76–79Google Scholar
  4. 4.
    Cassileth PA; Begg CB, Bennett JM et al (1984) A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 63: 843–847PubMedGoogle Scholar
  5. 5.
    Cassileth PA, Harrington DP, Hines JD et al (1988) Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 6 (4): 583–587PubMedGoogle Scholar
  6. 6.
    Champlin R, Gajewski J, Nimer S et al (1990) Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment. J Clin Oncol 8: 1199–1206PubMedGoogle Scholar
  7. 7.
    Hayat M, Jehn U,Willemze R et al (1986) A randomized comparison of maintenance treatment with androgens, immunotherapy and chemotherapy in adult acute myelogenous leukemia. Cancer 58: 617–623PubMedCrossRefGoogle Scholar
  8. 8.
    Kurrle E, Ehninger G, Fackler-Schwalbe E et al (1990) Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia. In Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias II. Springer, Berlin Heidelberg New York, pp 209–215 ( Hämatologie and Bluttransfusion, Vol 33 )Google Scholar
  9. 9.
    Preisler H, Davis RB, Kirshner Jet al. (1987) Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a Cancer and Leukemia Group B study. Blood 69: 1441–1449PubMedGoogle Scholar
  10. 10.
    Preisler HD, Raza A, Early A et al. (1987) Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 5: 722–730PubMedGoogle Scholar
  11. 11.
    Rai KR, Holland JF,, Glidewell OJ et al. (1981) Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 58: 1203–1212PubMedGoogle Scholar
  12. 12.
    Rees JKH, Swirsky D, Gray RG, Hayhoe FGJ (1986) Principal results of the Medical Research Council’s 8th Acute Myeloid Leukemia Trial. Lancet ii: 1236–1241Google Scholar
  13. 13.
    Sauter C, Fopp M, Imbach P et al. (1984) Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival. Lancet ii 379–382Google Scholar
  14. 14.
    Vogler WR, Winton EF, Gordon DS et al. (1984) A randomized comparison of post-remission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group Trial. Blood 63: 1039–1045PubMedGoogle Scholar
  15. 15.
    Wolff SN, Marion J, Stein RS et al. (1985) High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: a pilot study. Blood 65: 1407–1411PubMedGoogle Scholar
  16. 16.
    Yates J, Glidewell O, Wiernik P et al. (1982) Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood 60: 454–462PubMedGoogle Scholar
  17. 17.
    Zittoun R, Jehn U, Fière D et al. (1989) Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC leukemia Cooperative Group. Blood 73: 896–906PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • T. Büchner
    • 1
  1. 1.Department of Medicine, Hematology/OncologyUniversity of MünsterMünsterGermany

Personalised recommendations